Identify Genes/Pathways Responsible for Progression From Low Risk to Higher Risk Prostate Cancer

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Dec 26, 2018

Keywords

ClinConnect Summary

This clinical trial is studying how certain genes and pathways might influence the progression of low-risk prostate cancer to higher-risk forms of the disease. Prostate cancer is often detected early through PSA screenings, and many men diagnosed with low-risk prostate cancer may not need aggressive treatment right away. Instead, doctors often recommend monitoring the condition closely through methods like active surveillance, as many of these patients do not experience significant issues from the cancer. However, about 30% of these patients may eventually require treatment due to changes in their cancer. The goal of this trial is to identify specific genes that could indicate when low-risk prostate cancer is likely to progress, which could help doctors make better decisions about treatment and potentially prevent the disease from worsening.

To be eligible for this trial, participants must be adult males diagnosed with prostate cancer, specifically adenocarcinoma, and have undergone or are undergoing active surveillance at the National Taiwan University Hospital. They should also be scheduled for a prostate biopsy to check for any signs of disease progression. Participants can expect to contribute to important research that may improve future treatments for prostate cancer, and they will need to provide informed consent to join the study. This research is especially significant given the high number of men with this type of cancer, as it aims to enhance our understanding of how to manage and treat prostate cancer effectively.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Historically or cytologically confirmed adenocarcinoma of prostate.
• • 2. Have or ever received active Surveillance as the main conservative management at NTUH (National Taiwan University Hospital).
• • 3. Have or will receive prostate biopsy to confirm tumor progression after the diagnosis of prostate cancer.
• Exclusion Criteria:
• • 1. Have received systemic chemotherapy, pelvic radiotherapy or androgen deprivation therapy (ADT) before the obtainment of pathological specimen from prostate operation or biopsy.
• • 2. Subjects who disagree with signing the informed consent.